Last reviewed · How we verify
SAR231893
SAR231893 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.
SAR231893 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner. Used for Muscle wasting and weakness in aging males, Osteoporosis and bone loss.
At a glance
| Generic name | SAR231893 |
|---|---|
| Also known as | Dupixent |
| Sponsor | Sanofi |
| Drug class | Selective androgen receptor modulator (SARM) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Musculoskeletal |
| Phase | FDA-approved |
Mechanism of action
SAR231893 binds to and activates the androgen receptor with preferential activity in muscle and bone tissues while minimizing activity in prostate and other androgen-sensitive tissues. This selective tissue activation aims to provide anabolic benefits (muscle and bone strengthening) while reducing unwanted androgenic side effects associated with traditional androgens.
Approved indications
- Muscle wasting and weakness in aging males
- Osteoporosis and bone loss
Common side effects
- Testosterone suppression
- Liver enzyme elevation
- Headache
Key clinical trials
- A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. (PHASE4)
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
- Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid (PHASE2, PHASE3)
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis (PHASE3)
- Registry of Asthma Patients Initiating DUPIXENT®
- Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |